BackVertex Pharmaceuticals Incorporated Overview

Vertex Pharmaceuticals Incorporated Total Liabilities

Vertex Pharmaceuticals Incorporated's total liabilities is $7.2B.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$7.18B
↑ 4.58% YoYΔ $314.10M vs prior year quarter

Peer trimmed avg / median

Loading

Vertex Pharmaceuticals Incorporated Total Liabilities History

Loading

Vertex Pharmaceuticals Incorporated vs. peers: Total Liabilities Comparison

Loading

Vertex Pharmaceuticals Incorporated Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Vertex Pharmaceuticals Incorporated (VX1.DE) FAQ

As of the most recent data (June 2026), VX1.DE shows a total liabilities of $7.2B. That compares with $6.9B in the prior-year period — up 4.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, VX1.DE's total liabilities is now $7.2B (was $6.9B) — a 4.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Vertex Pharmaceuticals Incorporated is outperforming or lagging.

Tracking VX1.DE's total liabilities over time shows whether Vertex Pharmaceuticals Incorporated is scaling, shrinking, or reshaping that part of the business. The current reading is $7.2B That compares with $6.9B in the prior-year period — up 4.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Vertex Pharmaceuticals Incorporated's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $7.2B) with ownership activity and broader fundamentals.

Vertex Pharmaceuticals Incorporated's total liabilities is $7.2B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.